ProMIS Neurosciences Valuation Multiples

ProMIS Neurosciences Overview

About ProMIS Neurosciences

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Founded

2005

HQ

Employees

8

Website

promisneurosciences.com

Sectors

BiopharmaceuticalsBioTech

Financials (FY)

Revenue: —

EBITDA: ($40M)

EV

$106M

Valuation Multiples

Multiples.vc

Start free trial

ProMIS Neurosciences Financials

ProMIS Neurosciences reported last fiscal year revenue of — and negative EBITDA of ($40M).

In the same fiscal year, ProMIS Neurosciences generated ($40M) in EBITDA losses and had net loss of ($40M).

ProMIS Neurosciences P&L

In the most recent fiscal year, ProMIS Neurosciences reported revenue of — and EBITDA of ($40M).

ProMIS Neurosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

ProMIS Neurosciences Stock Performance

ProMIS Neurosciences has current market cap of $112M, and enterprise value of $106M.

ProMIS Neurosciences' stock price is $12.50.

ProMIS Neurosciences Valuation Multiples

ProMIS Neurosciences trades at (2.7x) EV/EBITDA.

ProMIS Neurosciences Financial Valuation Multiples

As of April 11, 2026, ProMIS Neurosciences has market cap of $112M and EV of $106M.

Equity research analysts estimate ProMIS Neurosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

ProMIS Neurosciences has a P/E ratio of (2.8x).

ProMIS Neurosciences Margins & Growth Rates

ProMIS Neurosciences' revenue in the last fiscal year grew by —.

ProMIS Neurosciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $5.0M for the same period.

ProMIS Neurosciences Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

ProMIS Neurosciences M&A Activity

ProMIS Neurosciences acquired XXX companies to date.

Last acquisition by ProMIS Neurosciences was on XXXXXXXX, XXXXX. ProMIS Neurosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

ProMIS Neurosciences Investment Activity

ProMIS Neurosciences invested in XXX companies to date.

ProMIS Neurosciences made its latest investment on XXXXXXXX, XXXXX. ProMIS Neurosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).